Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle
Source: The Street
Allergan caused a lot of hand-wringing in the biotech community and excitement among patent lawyers, when the drugmaker announced it would transfer patents for Restasis, Allergan's longstanding dry eye medication, to the Saint Regis Mohawk Tribe, according to a report on TheStreet.com.
The arrangement is a legal maneuver to shield Restasis, Allergan's second best-selling drug behind cosmetic treatment Botox, from patent challenges being waged by Mylan NV and others.
When Allergan announced the transfer on Sept. 8, a number of biotech players criticized the move, explaining that the unconventional move would draw unwanted attention from Washington, which is already concerned about the high price of branded drugs and the slow pace of approvals for price-restraining generics.
You must be logged in to leave a comment.